AbbVie Settles Lawsuit to Delay Generic Rinvoq Release Until 2037

AbbVie has settled a lawsuit with generic drug manufacturers to delay the release of a generic version of Rinvoq, an arthritis treatment, until April 2037. This decision positions Rinvoq and Skyrizi as potential successors to Humira, which lost its U.S. market exclusivity in 2023. Rinvoq's net sales reached $2.7 billion in the first half of 2025, marking a 53% increase year-over-year.

AbbVie has secured a significant victory in its legal battle with generic drug manufacturers, delaying the entry of generic versions of its blockbuster autoimmune drug Rinvoq until April 2037. The settlement, announced on September 11, 2025, extends the drug's exclusivity period by four years, ensuring AbbVie's continued control over the U.S. market for Rinvoq.

The settlement, which is subject to standard acceleration provisions, follows a series of lawsuits filed by generic manufacturers seeking to bring their copycat versions of Rinvoq to the U.S. market. The agreement, if pediatric exclusivity is granted, will keep these generics out of the domestic market until April 2037 AbbVie in Settlement With Generic Drugmakers on Rinvoq -- Update^[1].

Analysts at William Blair and BMO Capital Markets have hailed the settlement as a positive development for AbbVie. William Blair, who previously modeled a steep drop in Rinvoq sales after 2033, has now adjusted its expectations following the settlement. The firm now anticipates peak worldwide Rinvoq sales of $19 billion in 2033 and peak U.S. Rinvoq sales of $15 billion in 2036 AbbVie in Settlement With Generic Drugmakers on Rinvoq -- Update^[1].

Rinvoq's extended exclusivity positions the drug as a potential successor to Humira, which lost its U.S. market exclusivity in 2023. The settlement is a strategic move by AbbVie to bolster its franchise and offset the declining sales of its former mega-blockbuster. In the first half of 2025, Rinvoq's net sales reached $2.7 billion, marking a 53% year-over-year increase AbbVie Adds Four Years of Exclusivity to Rinvoq Franchise With Generics Settlement^[2].

AbbVie's shares recently surged following the announcement, reaching an all-time high of $221.77 and pushing the company's market capitalization to around $390 billion. The positive market reaction underscores investor confidence in AbbVie's ability to navigate the challenges posed by generic competition and maintain its market leadership in the autoimmune drug space AbbVie in Settlement With Generic Drugmakers on Rinvoq -- Update^[1].

The settlement is part of a broader strategy by AbbVie to diversify its revenue streams and maintain growth momentum. The company's focus on Rinvoq and fellow autoimmune drug Skyrizi is expected to drive significant revenue growth in the coming years, as indicated by AbbVie's recent earnings reports and analyst projections.

In conclusion, AbbVie's extended exclusivity for Rinvoq is a strategic win that positions the drug as a key successor to Humira. The settlement, combined with Rinvoq's strong sales performance and AbbVie's broader franchise, signals a promising outlook for the company's future growth.